Skip to main content

[Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer].

Der Urologe. Ausg. A

Authors: Dirk Beyersdorff, Kambiz Rahbar, Markus Essler, Ute Ganswindt, Anca-Ligia Grosu, Jürgen E Gschwend, Kurt Miller, Klemens Scheidhauer, Heinz-Peter Schlemmer, Johannes Maria Wolff, Bernd Joachim Krause

BACKGROUND: Numerous diagnostic and therapeutic innovations in the treatment of advanced prostate cancer, both in the hormone-sensitive and in the castration-resistant situation, recently led to a new orientation in the management of this tumor. However, there are potential indications beyond the ones covered by the S3 guideline on early detection, diagnosis and therapy of prostate cancer in clinical care that might be helpful for patients.

OBJECTIVES: Since July 2018, an interdisciplinary group of experts from nuclear medicine, radiologists, radio-oncologists and urologists developed a consensus paper on state-of-the-art innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer.

CONCLUSIONS: Provided by the working group are suggestions and strategies to improve the implementation of new imaging techniques such as multiparametric magnetic resonance imaging (mpMRI), PSMA-PET/CT (prostate-specific membrane antigen-positron emission tomography/computed tomography) and innovative therapeutic options (radium-223 dichloride, lutetium-177-PSMA) in the complex treatment of metastatic castration-resistant prostate cancer (mCRPC).

© 2021. The Author(s).

PMID: 34406465

Participating cluster members